Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adrenoceptor beta 2, surface | Starlite/ChEMBL | References |
Homo sapiens | adrenoceptor beta 3 | Starlite/ChEMBL | References |
Homo sapiens | adrenoceptor beta 1 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.1007 | 1 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.06 | 0.5133 | 0.5133 |
Loa Loa (eye worm) | carboxylesterase | 0.1007 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1007 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.1007 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.1007 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.1007 | 1 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.1007 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.06 | 0.5133 | 0.5133 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.017 | 0 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.1007 | 1 | 1 |
Onchocerca volvulus | 0.017 | 0 | 0.5 | |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.06 | 0.5133 | 0.5133 |
Echinococcus granulosus | acetylcholinesterase | 0.1007 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.1007 | 1 | 1 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.017 | 0 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.1007 | 1 | 1 |
Onchocerca volvulus | 0.017 | 0 | 0.5 | |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.017 | 0 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.06 | 0.5133 | 0.5133 |
Schistosoma mansoni | P2X receptor subunit | 0.06 | 0.5133 | 0.5133 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.06 | 0.5133 | 0.5133 |
Schistosoma mansoni | P2X receptor subunit | 0.06 | 0.5133 | 0.5133 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.017 | 0 | 0.5 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.06 | 0.5133 | 0.5133 |
Loa Loa (eye worm) | hypothetical protein | 0.1007 | 1 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.06 | 0.5133 | 0.5133 |
Onchocerca volvulus | 0.017 | 0 | 0.5 | |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.017 | 0 | 0.5 |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.017 | 0 | 0.5 |
Onchocerca volvulus | 0.017 | 0 | 0.5 | |
Echinococcus granulosus | p2X purinoceptor 4 | 0.06 | 0.5133 | 0.5133 |
Onchocerca volvulus | 0.017 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activation (functional) | = 70 % | In vitro efficacy at beta-3 adrenoceptors, quantified by measuring intracellular cAMP. | ChEMBL. | 10915043 |
Activation (functional) | = 70 % | In vitro efficacy at beta-3 adrenoceptors, quantified by measuring intracellular cAMP. | ChEMBL. | 10915043 |
EC50 (functional) | = 26 nM | In vitro efficacy at beta-3 adrenoceptors, quantified by measuring intracellular cAMP. | ChEMBL. | 10915043 |
EC50 (functional) | = 26 nM | In vitro efficacy at beta-3 adrenoceptors, quantified by measuring intracellular cAMP. | ChEMBL. | 10915043 |
IC50 (binding) | = 200 nM | In vitro binding affinity at beta-1 adrenergic receptors in the presence of [125]iodocyanopindolol. | ChEMBL. | 10915043 |
IC50 (binding) | = 200 nM | In vitro binding affinity at beta-1 adrenergic receptors in the presence of [125]iodocyanopindolol. | ChEMBL. | 10915043 |
IC50 (binding) | = 4000 nM | In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125]iodocyanopindolol. | ChEMBL. | 10915043 |
IC50 (binding) | = 4000 nM | In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125]iodocyanopindolol. | ChEMBL. | 10915043 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.